Last reviewed · How we verify
Trifarotene 0.005 % Topical Cream
Trifarotene is a retinoic acid receptor gamma (RAR-gamma) agonist that modulates the expression of genes involved in cell differentiation and proliferation.
Trifarotene is a retinoic acid receptor gamma (RAR-gamma) agonist that modulates the expression of genes involved in cell differentiation and proliferation. Used for Acne vulgaris.
At a glance
| Generic name | Trifarotene 0.005 % Topical Cream |
|---|---|
| Sponsor | Teva Pharmaceuticals USA |
| Drug class | retinoid |
| Target | RAR-gamma |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
By activating RAR-gamma, trifarotene influences the growth and differentiation of keratinocytes, which can help to reduce the severity of acne. This mechanism is thought to be responsible for the therapeutic effects of trifarotene in treating acne vulgaris.
Approved indications
- Acne vulgaris
Common side effects
- Skin irritation
- Dry skin
- Pruritus
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trifarotene 0.005 % Topical Cream CI brief — competitive landscape report
- Trifarotene 0.005 % Topical Cream updates RSS · CI watch RSS
- Teva Pharmaceuticals USA portfolio CI